WO2013120448A1 - 利奈唑胺中间体的制备方法 - Google Patents
利奈唑胺中间体的制备方法 Download PDFInfo
- Publication number
- WO2013120448A1 WO2013120448A1 PCT/CN2013/071576 CN2013071576W WO2013120448A1 WO 2013120448 A1 WO2013120448 A1 WO 2013120448A1 CN 2013071576 W CN2013071576 W CN 2013071576W WO 2013120448 A1 WO2013120448 A1 WO 2013120448A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- group
- fluoro
- formula
- bromide
- Prior art date
Links
- 0 *C[C@@](CN1c(cc2)cc(F)c2N2CCOCC2)OC1=O Chemical compound *C[C@@](CN1c(cc2)cc(F)c2N2CCOCC2)OC1=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the invention relates to a novel preparation process of a pharmaceutical intermediate, in particular to an important intermediate (S) -2- ((3-(3-fluoro-4-morpholinylphenyl))) involved in the synthesis of the antibacterial agent linezolid
- S important intermediate
- I 2-oxo-5-oxazoline methyl substituted compound
- Linezolid is a novel oxazolidinone antibacterial drug developed by Pharmacia & Upjohn (P&U).
- the drug acts on bacterial ribosomes and inhibits the synthesis of bacterial proteins.
- VRE vancomycin-resistant enterococci
- MRSA methicillin-resistant Staphylococcus aureus
- PRSP penicillin-resistant Streptococcus pneumoniae
- the route uses highly toxic phosgene.
- the subsequent reaction uses sodium azide and high-pressure catalytic hydrogenation. It has high requirements on equipment and has certain safety hazards, which is not conducive to industrial production.
- the first three steps of the route have lower reaction yields, resulting in higher production costs.
- the first step of the reaction is low in yield, and the configuration is easy to reverse.
- the ratio of product to isomer is about 85:15.
- the isomer is difficult to separate and will be brought into the subsequent reaction until the final product. Linezolid, affecting product quality. Summary of the invention
- the technical problem to be solved by the invention is to overcome the harsh conditions in the preparation process of the existing linezolid, high requirements on equipment, certain safety hazards, low yield, difficult separation of by-products, high cost and process. It is cumbersome and not conducive to industrial production and other defects.
- the present invention provides a novel synthetic method for a key intermediate (I) suitable for industrial production.
- the method comprises the following steps:
- the 3-fluoro-4-morpholine phenyl isocyanate (II) is cyclized with the epoxy compound (111) under the conditions of a reaction solvent and a catalyst to obtain a compound of the formula (I).
- the compound of formula (II) can be referred to Chinese Journal of Medicinal Chemistry, 2010, 20 ( 4 ), 287-2
- R group in the compound of formula ( ⁇ ) is a protected amine group, and "protected” as used herein has the commonly used meaning in the art, that is, to protect a group from reaction damage, it is first protected. Remove it after completion.
- the R group is preferably selected from the group consisting of:
- BOC represents a tert-butoxycarbonyl group
- Bn represents a benzyl group
- Cbz represents a benzyloxycarbonyl group
- R is most preferably a phthalimido group
- (S)-2-((3-(3-fluoro-4-morpholinyl)-2-oxo-5-oxazoline)methyl-substituted compound which has the structural formula shown in formula (I), is Lina An important intermediate in the synthesis of oxazolamide.
- the intermediate can be obtained by a related method described in the patent US2007032472 and a conventional method for removing a protecting group by a person skilled in the art, and after deacetylating, relining to obtain linezolid.
- R is a phthalimide group
- the subsequent reaction can be prepared as follows.
- the catalyst described in the cyclization reaction of the present invention is a Lewis acid or a mixture thereof, wherein the Lewis acid includes, but is not limited to, lithium bromide, magnesium bromide, lithium chloride, magnesium chloride, magnesium iodide, lithium iodide, Lithium chloride, zinc chloride, tetra-n-butylammonium bromide, tetra-n-butylammonium chloride or a mixture thereof, preferably lithium bromide, magnesium bromide, magnesium oxide or the like or any mixture thereof.
- the Lewis acid includes, but is not limited to, lithium bromide, magnesium bromide, lithium chloride, magnesium chloride, magnesium iodide, lithium iodide, Lithium chloride, zinc chloride, tetra-n-butylammonium bromide, tetra-n-butylammonium chloride or a mixture thereof, preferably lithium bromide, magnesium bromide, magnesium oxide or the like or any mixture thereof.
- the solvent described in the cyclization reaction of the present invention is an aprotic solvent or a mixture thereof, wherein the aprotic solvent includes, but is not limited to, ethyl acetate, butyl acetate, isoamyl acetate, toluene, xylene, chlorine Benzene, tetrahydrofuran, dichloromethane, N, N-dimethylformamide, C 6 -C 8 alkane, acetone, 1, 4-dioxane, acetonitrile or mixtures thereof, preferably butyl acetate, xylene, N , N-dimethylformamide, tetrahydrofuran, etc. or any mixture thereof.
- the aprotic solvent includes, but is not limited to, ethyl acetate, butyl acetate, isoamyl acetate, toluene, xylene, chlorine Benzene, tetrahydrofuran, dichlorome
- the temperature of the cyclization reaction of the present invention is from 60 ° C to 15 (TC, preferably from 100 to 140 ° C, particularly preferably from 115 to 125 ° C.
- the invention Compared with the prior art technology, the invention has the advantages that the improved process is simple, the reaction is mild, the total reaction yield is high, the purity is good, and the dangerous test is not required compared with other routes.
- the butyl lithium and sodium azide are easy to industrialize without harsh conditions such as ultra-low temperature. detailed description:
- the compound 3-fluoro-4-morpholine phenyl isocyanate (II) can be prepared by the method described in Chinese Journal of Medicinal Chemistry, 2010, 20 (4), 287-289, and the compound (III) and its similar structural compounds can be referred to. Made by the method described in EP 1 403 267.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13749142.9A EP2816039B1 (en) | 2012-02-15 | 2013-02-08 | Method for preparing linezolid intermediate |
US14/378,825 US9434702B2 (en) | 2012-02-15 | 2013-02-08 | Method for preparing linezolid intermediate |
JP2014556912A JP5938109B2 (ja) | 2012-02-15 | 2013-02-08 | リネゾリド中間体の調製方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210038198.3 | 2012-02-15 | ||
CN201210038198.3A CN103254148B (zh) | 2012-02-15 | 2012-02-15 | 利奈唑胺中间体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013120448A1 true WO2013120448A1 (zh) | 2013-08-22 |
Family
ID=48958414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/071576 WO2013120448A1 (zh) | 2012-02-15 | 2013-02-08 | 利奈唑胺中间体的制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9434702B2 (zh) |
EP (1) | EP2816039B1 (zh) |
JP (1) | JP5938109B2 (zh) |
CN (1) | CN103254148B (zh) |
WO (1) | WO2013120448A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103288814B (zh) * | 2012-02-24 | 2016-07-06 | 国药集团国瑞药业有限公司 | 一种利伐沙班中间体的制备方法 |
USRE47606E1 (en) * | 2016-04-21 | 2019-09-17 | Optimus Drugs Private Limited | Process for the preparation of linezolid |
WO2018055499A1 (en) * | 2016-09-20 | 2018-03-29 | Phalanx Labs Private Limited | One pot synthesis for the preparation of substituted phthalimido oxazolidinone antibacterials and oxazolidinone antiharombotics compounds by using recyclable heterogeneous catalyst |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007271A1 (en) | 1993-09-09 | 1995-03-16 | The Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
EP1403267A1 (en) | 2002-09-25 | 2004-03-31 | Daiso Co., Ltd. | Process for preparing glycidylphthalimide |
CN1772750A (zh) | 2005-11-15 | 2006-05-17 | 郑州大学 | (r)-n-(3-氟-4-吗啉苯基)-噁唑酮-5-甲基醇制备工艺 |
US20070032472A1 (en) | 2004-04-19 | 2007-02-08 | Symed Labs Limited | Novel process for the preparation of linezolid and related compounds |
WO2007116284A1 (en) | 2006-04-07 | 2007-10-18 | Pfizer Products Inc. | Process for preparing linezolid |
WO2011098501A1 (en) * | 2010-02-10 | 2011-08-18 | Sandoz Ag | Method for the preparation of rivaroxaban |
WO2011137222A1 (en) * | 2010-04-30 | 2011-11-03 | Indiana University Research And Technology Corporation | Processes for preparing linezolid |
CN102250076A (zh) * | 2011-05-27 | 2011-11-23 | 横店集团家园化工有限公司 | 一种利伐沙班中间体及利伐沙班的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107519A (en) * | 1997-11-07 | 2000-08-22 | Pharmacia & Upjohn Company | Process to produce oxazolidinones |
DE60118241T2 (de) * | 2000-10-17 | 2006-12-28 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Verfahren zur herstellung von oxazolidinonverbindungen |
CN103288814B (zh) * | 2012-02-24 | 2016-07-06 | 国药集团国瑞药业有限公司 | 一种利伐沙班中间体的制备方法 |
US9562040B2 (en) * | 2012-04-06 | 2017-02-07 | Indiana University Research And Technology Corporation | Processes for preparing Rivaroxaban |
CN102702125B (zh) * | 2012-05-10 | 2014-09-03 | 浙江工业大学 | 一种利奈唑胺的化学合成方法 |
-
2012
- 2012-02-15 CN CN201210038198.3A patent/CN103254148B/zh active Active
-
2013
- 2013-02-08 US US14/378,825 patent/US9434702B2/en active Active
- 2013-02-08 JP JP2014556912A patent/JP5938109B2/ja active Active
- 2013-02-08 WO PCT/CN2013/071576 patent/WO2013120448A1/zh active Application Filing
- 2013-02-08 EP EP13749142.9A patent/EP2816039B1/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995007271A1 (en) | 1993-09-09 | 1995-03-16 | The Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
EP1403267A1 (en) | 2002-09-25 | 2004-03-31 | Daiso Co., Ltd. | Process for preparing glycidylphthalimide |
US20070032472A1 (en) | 2004-04-19 | 2007-02-08 | Symed Labs Limited | Novel process for the preparation of linezolid and related compounds |
CN1772750A (zh) | 2005-11-15 | 2006-05-17 | 郑州大学 | (r)-n-(3-氟-4-吗啉苯基)-噁唑酮-5-甲基醇制备工艺 |
WO2007116284A1 (en) | 2006-04-07 | 2007-10-18 | Pfizer Products Inc. | Process for preparing linezolid |
WO2011098501A1 (en) * | 2010-02-10 | 2011-08-18 | Sandoz Ag | Method for the preparation of rivaroxaban |
WO2011137222A1 (en) * | 2010-04-30 | 2011-11-03 | Indiana University Research And Technology Corporation | Processes for preparing linezolid |
CN102250076A (zh) * | 2011-05-27 | 2011-11-23 | 横店集团家园化工有限公司 | 一种利伐沙班中间体及利伐沙班的制备方法 |
Non-Patent Citations (3)
Title |
---|
CHINESE JOURNAL OF MEDICINAL CHEMISTRY, vol. 20, no. 4, 2010, pages 287 - 289 |
GREGORY WALTER A ET AL.: "Antibacterials. synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The ''A'' group.", J.MED.CHEM., 1990, pages 2569 - 2578, XP002690794 * |
See also references of EP2816039A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2816039A4 (en) | 2015-07-15 |
US9434702B2 (en) | 2016-09-06 |
US20150011757A1 (en) | 2015-01-08 |
JP5938109B2 (ja) | 2016-06-22 |
CN103254148B (zh) | 2016-04-13 |
CN103254148A (zh) | 2013-08-21 |
EP2816039A1 (en) | 2014-12-24 |
JP2015506992A (ja) | 2015-03-05 |
EP2816039B1 (en) | 2017-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3200791B1 (en) | Processes and intermediates in the preparation of c5ar antagonists | |
KR100658959B1 (ko) | 텔미사르탄의 다형체, 이의 제조방법 및 이를 포함하는 약제 | |
EP1328509B1 (en) | Methods of producing oxazolidinone compounds | |
US20030216572A1 (en) | Process to produce oxazolidinones | |
CN103288814B (zh) | 一种利伐沙班中间体的制备方法 | |
WO2010081404A1 (zh) | 一种利奈唑胺的制备方法及其中间体 | |
US10927095B2 (en) | Processes for the preparation of Niraparib and intermediates thereof | |
EP3189053A2 (en) | An improved process for the preparation of apixaban and intermediates thereof | |
WO2013120448A1 (zh) | 利奈唑胺中间体的制备方法 | |
WO2016189552A2 (en) | Novel recovery and recycling process of unwanted enantiomers of 2-aminopropyl indoline derivatives | |
EP2163547A1 (en) | Process for the preparation of an oxazolidinone antibacterial agent and intermediates thereof | |
TW202140457A (zh) | 用於製備呔𠯤酮衍生物及其中間體之製程 | |
CN111072660B (zh) | 一种瑞来巴坦的简便制备方法 | |
WO2012171248A1 (zh) | 1,3-噁唑烷-2-酮类化合物、其制备方法和用途 | |
JP6972033B2 (ja) | 光学活性ピロリジン化合物の製造方法 | |
CN107935866B (zh) | 盐酸达泊西汀杂质的制备方法 | |
US10053460B2 (en) | Process for the preparation of tert-butyl 4-((2S ,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof | |
AU2008247136B2 (en) | Process for preparing valsartan | |
RU2742765C1 (ru) | Способ получения промежуточного соединения для синтеза лекарственного средства | |
JP5279449B2 (ja) | 5−{4−[2−(5−エチル−2−ピリジル)エトキシ]ベンジル}−2,4−チアゾリジンジオン塩酸塩の製造方法 | |
HUE032850T2 (en) | Rivaroxaban intermediate and its preparation | |
CN104370854B (zh) | 3-卤-2-羟基丙基-1-酰基苯胺类化合物其制备方法和用途 | |
CN106749073B (zh) | 一种利奈唑胺的制备方法 | |
CN103787944A (zh) | 1-(2-氯乙酰基)-2-(s)-腈基吡咯烷的制备方法 | |
WO2015162622A1 (en) | Process for preparation of linezolid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13749142 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2013749142 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013749142 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014556912 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14378825 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |